Read more about the article Responsive Approaches: Adapting Our Work to the New Realities of COVID-19
Work desk with a lighted lamp and computers, working from home

Responsive Approaches: Adapting Our Work to the New Realities of COVID-19

As FHI Clinical begins supporting rapid start-up of clinical trials vital to containing the spread of COVID-19 and protecting the global community, we are also adapting our ongoing work to the new reality of this global pandemic. We are closely monitoring the situation on the ground in the countries where we work and repurposing team members to support COVID-19 response needs.

Continue ReadingResponsive Approaches: Adapting Our Work to the New Realities of COVID-19
Read more about the article A Unique Public-Private Partnership to Eradicate Malaria in Equatorial Guinea

A Unique Public-Private Partnership to Eradicate Malaria in Equatorial Guinea

One example of the ability of public-private partnerships to establish and strengthen research capacity is the Equatorial Guinea Malaria Initiative (EGMVI), which began within the larger Bioko Island Malaria Control Project (BIMCP). Last year, the two were combined into the Bioko Island Malaria Elimination Project (BIMEP). Dr Stephen Hoffman from Sanaria, Inc. shared details of the BIMEP with us. FHI Clinical has also had the privilege of being involved in studies conducted by the EGMVI (now BIMEP).

Continue ReadingA Unique Public-Private Partnership to Eradicate Malaria in Equatorial Guinea
Read more about the article Providing Site Monitoring and Management Expertise in Malaria Vaccine Trials in Equatorial Guinea

Providing Site Monitoring and Management Expertise in Malaria Vaccine Trials in Equatorial Guinea

Data monitoring strategies implemented by our bilingual CRA helped eliminate the backlog to ensure timely database lock in a phase 2 trial for Sanaria's innovative PfSPZ Vaccine for malaria in Equatorial Guinea, an area with limited prior research experience.

Continue ReadingProviding Site Monitoring and Management Expertise in Malaria Vaccine Trials in Equatorial Guinea